Drug profile · INN
visilizumab
visilizumab is a t-cell surface glycoprotein cd3 epsilon chain inhibitor.
NMPA: clinical trials
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — visilizumab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.70
Quick answer
visilizumab is a t-cell surface glycoprotein cd3 epsilon chain inhibitor.
Key facts
INN visilizumab
Mechanism T-cell surface glycoprotein CD3 epsilon chain inhibitor
Target T-cell surface glycoprotein CD3 epsilon chain
Mechanism of action
T-cell surface glycoprotein CD3 epsilon chain inhibitor
Primary target: T-cell surface glycoprotein CD3 epsilon chain
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is visilizumab?
visilizumab is a t-cell surface glycoprotein cd3 epsilon chain inhibitor.